How to Appeal a Coverage Decision About Zepbound
An appeal starts with an internal review filed against the written denial, and where that fails, most people can escalate to a reviewer outside the plan. Which ladder applies is set by who carries the financial risk: a self-funded employer plan, a state-regulated insured plan, a marketplace policy, a Medicare drug plan or Medicaid each run a different sequence with different deadlines.
Identify the ladder before drafting anything
The same letter means different things depending on the plan behind it. An employer that pays its own claims is governed by federal benefit law and its appeals run through the plan administrator, with external review handled under the federal process. An employer that buys insurance from a carrier is subject to that state’s insurance rules, and the external stage is run by the state department of insurance or its contracted reviewers.
Medicare drug plans sit entirely outside both. So does Medicaid, where the escalation is a state fair hearing rather than a private review. Advice written for one of these markets misleads people in the others, which is why so many appeals are filed to the wrong address on the wrong form.
The ladders side by side
| Plan type | First stage | Escalation | Decided finally by |
|---|---|---|---|
| Self-funded employer | Internal appeal to the plan | Federal external review | Independent review organization |
| Fully insured employer | Internal appeal to the carrier | State external review | State-assigned reviewer |
| Marketplace or individual | Internal appeal to the issuer | State or federal external review | Independent review organization |
| Medicare drug plan | Redetermination by the plan | Independent review entity, then a hearing | Administrative law judge and above |
| Medicaid | Plan-level appeal | State fair hearing | State hearing officer |
The denial letter is the specification
A written adverse determination has to state the reason and the rule relied on, and it must explain how to appeal and by when. Read it for two things. First, whether the refusal rests on clinical judgment, such as criteria not met, or on the contract, such as a category the plan does not cover. Second, which criteria document was applied, by name and version.
That distinction governs everything downstream. External review is designed for disputes involving medical judgment. A pure benefit exclusion, where the employer bought a plan that omits anti-obesity medication, is generally not eligible for external review at all, because there is no clinical question in dispute. Filing anyway costs weeks and produces a letter saying the request falls outside the process.
Deadlines that end the argument if missed
Group health plan members generally have 180 days from the date of an adverse determination to file an internal appeal. A request for external review is normally due within four months of the final internal decision. Medicare drug plan members have 60 days to ask for a redetermination, and each later level carries its own window. Expedited tracks exist across all of these where delay would seriously jeopardize health, and they compress decisions to a matter of days.
Calendar those dates the day the letter arrives. Appeals lost on timing are the most avoidable category of failure, and plans are under no obligation to accept a late filing.
What actually changes a reviewer’s mind
Reviewers respond to the record, not to the strength of feeling in the letter. The material that moves cases is dated measurements, coded diagnoses, a documented history of what was tried and what happened, and a clinical statement explaining why this agent suits this patient. Current pharmacotherapy guidance frames drug selection as a match between an individual’s profile and a given medication, which gives a prescriber concrete language to work with.
Two further items carry weight. Where obstructive sleep apnea is present, the sleep study report matters, since this drug carries a separate approved indication for moderate to severe obstructive sleep apnea in adults with obesity and the supporting trial reported reductions in apnea-hypopnea index against placebo. And where a prior course was interrupted, evidence of response before the interruption is persuasive, because maintenance trials show that weight returns once treatment stops.
The exclusion appeal is the one that mostly fails
Before pouring effort into an appeal that is unlikely to move, it helps to know what the drug costs without the plan, since that figure often decides whether the fight is worth having. Several providers publish cash pricing that can be compared in a few minutes: HealthRX lists a dedicated Zepbound page, and Henry Meds and LillyDirect post their own monthly numbers. Recording the maintenance-dose price from a couple of them turns a vague worry into a figure a household can plan around.
When the contract simply does not include the category, the honest assessment is that an appeal is unlikely to succeed, and the productive conversation is with the employer rather than the insurer. Benefits teams do reconsider designs at renewal, and member interest is one of the inputs.
Meanwhile the practical question is what treatment costs without the plan. Manufacturer self-pay pricing for the branded product is published and is the first figure to obtain. Several supervised telehealth practices sell compounded tirzepatide and semaglutide on a flat monthly basis, among them Ro, LifeMD, Hims and Hers and FormBlends, and those compounded products are prepared by pharmacies rather than approved by the FDA, which does not review them for safety, effectiveness or quality. Knowing both numbers before the appeal concludes prevents an unplanned interruption if the answer stays no.
Filing the appeal in a form the plan can process
Send it in writing, reference the claim or case number from the denial, state plainly what decision is being contested, and attach the clinical documentation as exhibits rather than describing it. Request a copy of the full case file, which plans are typically required to provide on request, since it reveals exactly which criterion the reviewer marked unmet. Ask the prescribing office to request a peer-to-peer discussion in parallel, because a five-minute clinician conversation sometimes resolves what a written exchange cannot.
Frequently asked questions
Does appealing pause the need to pay for medication?
No. Coverage is not reinstated while a review is pending, so any doses taken in the interim are self-funded. Some plans reimburse retroactively when an appeal succeeds, and others do not. Asking about retroactive payment in writing before spending several months out of pocket is worthwhile.
Can someone else file on a member’s behalf?
Yes, with authorization. A prescriber can act as an authorized representative on most plans, and a family member can be appointed using the plan’s own form. Medicare drug appeals have a specific representative appointment form, and submissions without it are routinely returned unprocessed.
Is an external review decision binding on the plan?
Generally yes. Under the federal external review process the independent organization’s determination binds the plan, which is what makes that stage worth reaching. It only applies where the dispute involves medical judgment, so contract exclusions usually do not qualify for it.
How many times can the same request be appealed?
Commercial plans typically allow one or two internal levels followed by one external review. Medicare drug appeals run five levels, ending in federal court. Repeating an identical submission at the same level rarely helps, whereas adding evidence that addresses the stated reason often does.
Does a new prescription restart the process?
Sometimes. A materially different request, such as a different indication with new documentation, is normally treated as a new determination with fresh appeal rights. Resubmitting the same request unchanged is usually treated as a duplicate and closed.
